Living Cell Technologies Stock Performance
| LVCLF Stock | USD 0 0.00 0.00% |
Living Cell has a performance score of 1 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 17.98, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Living Cell will likely underperform. Living Cell Technologies right now secures a risk of 10.58%. Please verify Living Cell Technologies variance, as well as the relationship between the potential upside and day median price , to decide if Living Cell Technologies will be following its current price movements.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Living Cell Technologies are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain essential indicators, Living Cell may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
| Begin Period Cash Flow | 1.6 M | |
| Total Cashflows From Investing Activities | 39.5 K |
Living |
Living Cell Relative Risk vs. Return Landscape
If you would invest 0.65 in Living Cell Technologies on September 3, 2024 and sell it today you would lose (0.22) from holding Living Cell Technologies or give up 33.85% of portfolio value over 90 days. Living Cell Technologies is currently producing 0.1796% returns and takes up 10.5775% volatility of returns over 90 trading days. Put another way, 94% of traded pink sheets are less volatile than Living, and 97% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Living Cell Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Living Cell's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Living Cell Technologies, and traders can use it to determine the average amount a Living Cell's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.017
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LVCLF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.58 actual daily | 94 94% of assets are less volatile |
Expected Return
| 0.18 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Living Cell is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Living Cell by adding it to a well-diversified portfolio.
Living Cell Fundamentals Growth
Living Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Living Cell, and Living Cell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Living Pink Sheet performance.
| Return On Equity | -0.72 | |||
| Return On Asset | -0.31 | |||
| Operating Margin | (428.70) % | |||
| Current Valuation | 12.53 M | |||
| Shares Outstanding | 1.29 B | |||
| Price To Earning | (31.67) X | |||
| Price To Book | 6.96 X | |||
| Price To Sales | 5,587 X | |||
| Revenue | 3.4 K | |||
| EBITDA | (2.38 M) | |||
| Cash And Equivalents | 4.24 M | |||
| Total Debt | 228.44 K | |||
| Debt To Equity | 0.10 % | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (2.04 M) | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 4.27 M | |||
| Retained Earnings | (67 M) | |||
| Current Asset | 6 M | |||
| Current Liabilities | 1000 K | |||
About Living Cell Performance
By analyzing Living Cell's fundamental ratios, stakeholders can gain valuable insights into Living Cell's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Living Cell has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Living Cell has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. The company was founded in 1987 and is based in Sydney, Australia. Living Cell operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Living Cell Technologies performance evaluation
Checking the ongoing alerts about Living Cell for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Living Cell Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Living Cell had very high historical volatility over the last 90 days | |
| Living Cell has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 3.4 K. Net Loss for the year was (1.96 M) with profit before overhead, payroll, taxes, and interest of 3.4 K. | |
| Living Cell Technologies has accumulated about 4.24 M in cash with (2.04 M) of positive cash flow from operations. | |
| Roughly 34.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from benzinga.com: Insider Decision Steven H Collis Offloads 12.20M Worth Of Cencora Stock |
- Analyzing Living Cell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Living Cell's stock is overvalued or undervalued compared to its peers.
- Examining Living Cell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Living Cell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Living Cell's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Living Cell's pink sheet. These opinions can provide insight into Living Cell's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Living Pink Sheet analysis
When running Living Cell's price analysis, check to measure Living Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Living Cell is operating at the current time. Most of Living Cell's value examination focuses on studying past and present price action to predict the probability of Living Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Living Cell's price. Additionally, you may evaluate how the addition of Living Cell to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |